Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies

site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
Drug Category: Array
Conference Category: Array
Lead Author: Robertson D, et. al
Published Date: 17/04/2024
Download Link: /wp-content/uploads/2024/04/Radiological-Disease-Activity-AAN-2024-Robertson.pdf
Download Text:
Popup Confirmation?:
astra-migrate-meta-layouts: set
Scroll to Top